MARKET

NAVB

NAVB

NAVIDEA BIOPHARM
AMEX

Real-time Quotes | Nasdaq Last Sale

2.250
-0.080
-3.43%
Opening 15:45 03/03 EST
OPEN
2.315
PREV CLOSE
2.330
HIGH
2.330
LOW
2.200
VOLUME
192.40K
TURNOVER
--
52 WEEK HIGH
5.36
52 WEEK LOW
0.6300
MARKET CAP
60.05M
P/E (TTM)
-4.3512
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic...
BusinessWire - BZX · 23h ago
BRIEF-Navidea Biopharmaceuticals Announces $5 Million Private Placement With Existing Investor
reuters.com · 1d ago
Navidea Biopharmaceuticals launches $5M private placement with existing investor
Navidea Biopharmaceuticals (NAVB) trades 3.7% down premarket after executing an agreement with its largest shareholder, John K. Scott, Jr., to purchase $5M newly-designated series E redeemable convertible preferred stock.Over the upcoming 18 months, the
Seekingalpha · 1d ago
Navidea Biopharmaceuticals Announces $5M Private Placement Of Series E Redeemable Convertible Preferred Stock With Existing Investor John K. Scott, Jr
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that
Benzinga · 1d ago
Nanopharmaceuticals Market Size 2020 by Key Players, Growth Factors, Regions and Applications, Industry Forecast to 2024 Research Report by Absolute Reports
Feb 22, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Nanopharmaceuticals are colloidal...
The Express Wire · 02/22 11:07
Sentinel Node Biopsy Market Segmentation and Analysis by Recent Trends, consumption by Regional data, Development, Investigation, Global Growth by to 2026
Feb 11, 2021 (The Expresswire) -- Global “Sentinel Node Biopsy Market” (2021-2026) to its vast repository provides important statistics Centre’s on worldwide...
The Express Wire · 02/11 17:41
The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 9)
Benzinga · 02/09 13:10
Navidea Biopharmaceuticals Files Mixed Shelf for Up to $100 Million in Securities
MT Newswires · 02/09 03:21
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NAVB. Analyze the recent business situations of NAVIDEA BIOPHARM through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NAVB stock price target is 7.50 with a high estimate of 8.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 32
Institutional Holdings: 742.82K
% Owned: 2.78%
Shares Outstanding: 26.69M
TypeInstitutionsShares
Increased
7
158.08K
New
5
36.74K
Decreased
8
25.91K
Sold Out
24
84.02K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.70%
Pharmaceuticals & Medical Research
-1.59%
Key Executives
Chairman/Independent Director
Michael Rice
Chairman/Independent Director
Y. Michael Rice
Chief Executive Officer/Chief Financial Officer/Chief Operating Officer/IR Contact Officer
Jed Latkin
Other
Michael Rosol
Director
Malcolm Witter
Independent Director
Claudine Bruck
Independent Director
Kathy Rouan
Independent Director
Adam Cutler
Independent Director
S. Kathryn Rouan
  • Dividends
  • Splits
  • Insider Activity
No Data
About NAVB
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Company focuses on two types of drug products diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of Manocept platform, and NAV4694; and therapeutic development programs, including therapeutic applications of Manocept platform.

Webull offers kinds of Navidea Biopharmaceuticals Inc stock information, including AMEX:NAVB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NAVB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NAVB stock methods without spending real money on the virtual paper trading platform.